Invitrogen™ Crizanlizumab Humanized Recombinant Human Monoclonal Antibody, > 90%

The Invitrogen™ Crizanlizumab Humanized Recombinant Human Monoclonal Antibody is a recombinant IgG2SA humanized antibody expressed in Chinese Hamster Ovary (CHO) cells, designed for research applications involving selectin P (SELP) targeting.

Crizanlizumab (biosimilar form) specifically binds to P-selectin, a cell adhesion molecule that mediates interactions between endothelial cells, platelets, and leukocytes — a key pathway in inflammation, thrombosis, and vaso-occlusive crises.

This antibody can be used for a range of functional, biochemical, and analytical assays, including ELISA, flow cytometry, surface plasmon resonance (SPR), and cell-based functional studies.

Key Features

• High Purity: Verified by SDS-PAGE (>90% purity under reducing conditions).
• Recombinant Expression: Produced in CHO cells under controlled, serum-free conditions.
• Humanized Monoclonal: Engineered IgG2SA format for consistent binding affinity and reduced immunogenicity.
• Biosimilar Targeting: Specifically recognizes P-selectin (SELP) with high specificity.
• Lyophilized Format: Ensures extended stability for long-term storage and global shipment.
• Versatile Applications: Suitable for biochemical, biophysical, and cellular assays (e.g., ELISA, SPR, Flow).

Applications

Validated Example:

SDS-PAGE analysis under reducing conditions confirmed a single dominant band corresponding to Crizanlizumab heavy and light chains, verifying structural integrity and >90% protein purity.

Product Specifications

Reconstitution Instructions

1. Reconstitute the lyophilized antibody with sterile distilled water to a final concentration of 1 mg/mL.
2. Gently swirl or invert the vial until fully dissolved. Do not vortex.
3. After reconstitution, store aliquots at –80 °C for long-term use.
4. Avoid repeated freeze-thaw cycles to maintain antibody stability.

Target Information – SELP (P-Selectin)

Full Name: Selectin P (Platelet Selectin)

Protein Function:

• Mediates leukocyte–endothelium and platelet–endothelium adhesion during inflammation.
• Plays a role in vaso-occlusion, thrombosis, and inflammatory signaling.
• Therapeutic target in diseases involving vascular occlusion such as sickle cell disease.

Research Applications:

• Studying platelet activation and endothelial interactions.
• Inhibitor screening for P-selectin signaling pathways.
• Development of biosimilars and anti-inflammatory therapeutic antibodies.

Quality Validation

• SDS-PAGE: ≥90% purity (reducing conditions).
• Functional testing: SELP binding and inhibition confirmed.
• Consistency: Lot-to-lot performance verified under controlled expression and purification.

Storage and Stability

• Lyophilized form: Stable at –20 °C for extended periods.
• Reconstituted antibody: Store in aliquots at –80 °C.
• Avoid multiple freeze-thaw cycles to preserve structure and binding activity.

Advantages

• Humanized recombinant antibody for SELP pathway studies.
• Excellent purity and reproducibility.
• Compatible with biochemical and biophysical assays.
• No preservatives; suitable for downstream functional testing.
• Available in 100 µg and 1 mg package sizes for flexible experimental needs.

The Invitrogen™ Crizanlizumab Humanized Recombinant Monoclonal Antibody (Catalog #MA5-58387, #MA5-58388) is a high-purity humanized IgG2SA antibody that specifically targets P-selectin (SELP).

Produced in CHO cells and purified via Protein A chromatography, this antibody is ideal for biochemical, cellular, and functional assays including ELISA, flow cytometry, and SPR.

Its biosimilar design, high purity (>90%), and broad compatibility make it an excellent tool for research into vascular biology, thrombosis, and inflammation mechanisms.